

Appendix A. Supplemental tables [posted as supplied by author]

Table A. Incidence of myocardial infarction and death due to coronary heart disease stratified by follow-up time.

	MI/CHD death		Non-fatal MI		CHD death	
	N	Incidence (95% CI)	N	Incidence (95% CI)	N	Incidence (95% CI)
Total follow-up period	1222	9.58 (9.06–10.14)	876	6.87 (6.43–7.34)	346	2.71 (2.44–3.02)
First year of follow-up	451	12.92 (11.78–14.17)	324	9.28 (8.32–10.35)	127	3.64 (3.06–4.33)
Rest of follow-up	771	8.33 (7.76–8.94)	552	5.96 (5.48–6.48)	219	2.37 (2.07–2.70)

NOTE: incidence is given per 1000 person-years.

Table B. Incidence of myocardial infarction and death due to coronary heart disease according to sex, age and low-dose acetylsalicylic acid indication.

	MI/CHD death		Non-fatal MI		CHD death	
	N	Incidence (95% CI)	N	Incidence (95% CI)	N	Incidence (95% CI)
Sex						
Male (N = 22 122)	810	11.41 (10.65–12.22)	566	7.97 (7.34–8.66)	244	3.44 (3.03–3.90)
Female (N = 17 391)	412	7.29 (6.62–8.03)	310	5.49 (4.91–6.13)	102	1.81 (1.49–2.19)
Age^a						
50–64 years (N = 14 754)	357	7.07 (6.37–7.84)	282	5.59 (4.97–6.28)	75	1.49 (1.18–1.86)
65–74 years (N = 13 715)	447	9.28 (8.46–10.18)	337	7.00 (6.29–7.78)	110	2.28 (1.89–2.75)
75–84 years (N = 11 044)	418	14.49 (13.16–15.95)	257	8.91 (7.88–10.07)	161	5.58 (4.78–6.51)
Low-dose acetylsalicylic indication						
CVD (N = 12 771)	267	6.82 (6.05–7.69)	179	4.57 (3.95–5.29)	88	2.25 (1.82–2.77)
IHD (N = 16 592)	530	9.01 (8.27–9.81)	391	6.65 (6.02–7.34)	139	2.36 (2.00–2.79)
UA (N = 764)	37	14.66 (10.62–20.22)	27	10.69 (7.33–15.59)	10	3.96 (2.13–7.36)
MI (N = 9386)	388	14.38 (13.02–15.88)	279	10.34 (9.19–11.63)	109	4.04 (3.35–4.87)

^aAge at the start of follow-up.

CVD, cerebrovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; UA, unstable angina.

NOTE: incidence is given per 1000 person-years.

Table C. Relative risk of myocardial infarction and death due to coronary heart disease according to discontinuation of other medications.

	Controls N = 5000	MI/CHD cases N = 1222	Crude RR^a (95% CI)	RR^b (95% CI)
Inhaled beta-agonists				
Current (use on index date)	361 (7.2)	129 (10.6)	1 (–)	1 (–)
Indeterminate (stopped 1–30 days before index date)	92 (1.8)	27 (2.2)	0.81 (0.50–1.29)	0.94 (0.57–1.57)
Recent discontinuers (stopped 31–180 days before index date)	165 (3.3)	49 (4.0)	0.85 (0.58–1.24)	1.05 (0.70–1.58)
Past discontinuers (stopped 181–365 days before index date)	76 (1.5)	20 (1.6)	0.77 (0.45–1.32)	1.02 (0.57–1.82)
Inhaled steroids				
Current (use on index date)	244 (4.9)	95 (7.8)	1 (–)	1 (–)
Indeterminate (stopped 1–30 days before index date)	91 (1.8)	30 (2.5)	0.86 (0.53–1.39)	0.93 (0.56–1.55)
Recent discontinuers (stopped 31–180 days before index date)	132 (2.6)	25 (2.1)	0.50 (0.30–0.81)	0.58 (0.35–0.98)
Past discontinuers (stopped 181–365 days before index date)	28 (0.6)	9 (0.7)	0.86 (0.39–1.90)	1.28 (0.56–2.92)
Insulin				
Current (use on index date)	137 (2.7)	58 (4.8)	1 (–)	1 (–)
Indeterminate (stopped 1–30 days before index date)	11 (0.2)	2 (0.2)	0.44 (0.09–2.07)	0.63 (0.13–3.01)
Recent discontinuers (stopped 31–180 days before index date)	10 (0.2)	2 (0.2)	0.48 (0.10–2.25)	0.42 (0.08–2.20)
Past discontinuers (stopped 181–365 days before index date)	4 (0.1)	0 (–)	–	–
PPIs				
Current (use on index date)	770 (15.40)	264 (21.60)	1 (–)	1 (–)
Indeterminate (stopped 1–30 days before index date)	148 (2.96)	47 (3.85)	0.92 (0.64–1.32)	0.88 (0.60–1.29)
Recent discontinuers (stopped 31–180 days before index date)	168 (3.36)	46 (3.76)	0.80 (0.56–1.14)	0.90 (0.61–1.31)
Past discontinuers (stopped 181–365 days before index date)	120 (2.40)	16 (1.31)	0.38 (0.22–0.66)	0.41 (0.23–0.72)

^aAdjusted for the matched variables: sex, age and calendar year

^bAdjusted for age, sex, calendar year, time to event, smoking, ischaemic heart disease (at start date), cerebrovascular disease (at start date), diabetes (at start date), chronic obstructive pulmonary disease (at start date), and use of clopidogrel, statins, anticoagulants, nitrates, antihypertensives, oral steroids, non-steroidal anti-inflammatory drugs and acetylsalicylic acid.

Note: To calculate the estimate of oral antidiabetics as well as insulin we removed diabetes from the multivariable model.